Preliminary Results From A Multicenter, Single-Arm, Phase 2 Study Of Cs1001, An Anti-Programmed Death-Ligand 1 (Pd-L1) Human Monoclonal Antibody (Mab), In Patients (Pts) With Relapsed Or Refractory Extranodal Natural Killer/T Cell Lymphoma (Rr-Enktl)